N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2) is a member of the glutamate carboxypeptidase II family, best characterized by prostate-specific membrane antigen (PSMA/NAALAD1). Using immunohistochemistry (IHC), we have shown overexpression of NAALADL2 in colon and prostate tumours when compared with benign tissue. In prostate cancer, NAALADL2 expression was associated with stage and Grade, as well as circulating mRNA levels of the NAALADL2 gene. Overexpression of NAALADL2 was shown to predict poor survival following radical prostatectomy. In contrast to PSMA/NAALAD1, NAALADL2 was localized at the basal cell surface where it promotes adhesion to extracellular matrix proteins. Using stable knockdown and overexpression cell lines, we have demonstrated NAALADL2-dependent changes in cell migration, invasion and colony-forming potential. Expression arrays of the knockdown and overexpression cell lines have identified nine genes that co-expressed with NAALADL2, which included membrane proteins and genes known to be androgen regulated, including the prostate cancer biomarkers AGR2 and SPON2. Androgen regulation was confirmed in a number of these genes, although NAALADL2 itself was not found to be androgen regulated. NAALADL2 was also found to regulate levels of Ser133 phosphorylated C-AMP-binding protein (CREB), a master regulator of a number of cellular processes involved in cancer development and progression. In combination, these data suggest that changes in expression of NAALADL2 can impact upon a number of pro-oncogenic pathways and processes, making it a useful biomarker for both diagnosis and prognosis.
INTRODUCTION
The N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase) family, also known as glutamate carboxypeptidase II and N-acetylaspartylglutamate (NAAG) peptidase, are characterized by their ability to act as M28 membrane metalloproteases and catalyse the hydrolysis of NAAG to glutamate and N-acetylaspartate. 1, 2 The best characterized member of the NAALADase family is prostate-specific membrane antigen (PSMA) that was identified in the prostate cancer LNCaP cell line and subsequently characterized as a prostate cancer biomarker and drug target. [3] [4] [5] Studies on PSMA/NAALAD1 have shown that NAALADase activity relies upon an active site glutamic acid residue (E 424 ) and zinc binding for its enzymatic function. However, calcium binding and glycosylation at amino acids distant to the active site have also been shown to maintain the protein structure and regulate NAALADase activity. 1, 6, 7 Previously, the NAALADL2-associated rs17531088 risk allele has been linked to Kawasaki disease that affects the blood vessels and can lead to death.
8 NAALADL2 was also identified as the site of a break point leading to Cornelia de Lange syndrome, a rare developmental malformation syndrome characterized by mental handicap, growth retardation, distinctive facial features and limb defects. 9 Prostate cancer is the most common male solid malignancy diagnosed in men in the United Kingdom. 10 Risk stratification of this heterogeneous disease is currently carried out using predictive models based on clinical variables such as age, disease stage, Gleason grade and serum prostate-specific antigen (PSA) measurements. [11] [12] [13] Although these predictive tools are practical and convenient, they may not be able to identify all patients at risk of disease progression, relapse or those low-risk patients most suitable for surveillance. Although there are large numbers of potential molecular biomarkers in the literature, only PSA, and to some extent PCA3, is used routinely to assist in diagnosis despite their sub-optimal sensitivity and specificity. 14, 15 Unlike PCA3, PSA has shown some promise in predicting aggressive disease and relapse following treatment, but this remains an area of prostate research where novel markers could significantly impact on clinical decisions. that NAALADL2 protein is expressed in a number of cancers and highly expressed in prostate cancer where it predicts for relapse following radical prostatectomy. We show that unlike PSMA/ NAALAD1,which is expressed at the apical membrane, NAALADL2 is localized to the basal membrane where it promotes invasion, migration and alters the ability of cells to bind to components of the extracellular matrix. Using expression arrays of stable overexpressing and knocked-down NAALADL2, we have shown that NAALADL2 is co-expressed alongside known androgen-regulated genes and known prostate cancer biomarkers. We believe that NAALADL2 may have a role in establishing a pro-oncogenic and aggressive tumour microenvironment.
RESULTS

NAALADL2 is overexpressed in cancer tissues
Using paraffin-embedded cell pellets to establish antibody specificity (Supplementary Figure S1 ), NAALADL2 IHC was developed and used to stain a multi-tumour/normal tissue microarray (TMA) ( Table 1 ). In all tissue types that stained positively, NAALADL2 expression was noted at the basal cell surface and in the perinuclear region, consistent with the Golgi (Figures 1a and  3a) . The majority of normal tissues showed weak or undetectable NAALADL2 expression with the exception of moderate staining in the kidney and stomach. There was low expression in a number of tumour tissues, and moderate expression was seen in tongue, pancreas and breast cancers. NAALADL2 was highly overexpressed in colon and prostate cancers. NAALADL2 overexpression in tumours was confirmed using commercially available TMAs for colon, breast and pancreatic cancers with only NAALADL2 in colon cancer showing any significant ability to distinguish between benign and tumour tissue (P ¼ 0.05 using a cutoff X weak staining) ( Figure 1b ). There were insufficient numbers to establish links to other prognostic factors.
NAALADL2 overexpression in prostate cancer was confirmed using a (Cambridge) TMA, and could distinguish between benign and tumour tissue with a high degree of sensitivity and specificity (sensitivity, 86%, specificity 86%, Po0.0001 using a cutoff X moderate staining, Figure 1c ). This was supported by an additional radical prostatectomy TMA in collaboration with the Karolinska Institute that confirmed that NAALADL2 could differentiate between benign and tumourigenic prostate tissue (Po0.0001, Figure 1d ). Using the Cambridge TMA, NAALADL2 expression was shown to increase significantly with increasing Gleason grade (P ¼ 0.028, Figure 1e ) and pathological stage (P ¼ 0.004, Figure 1f ), in particular between pT2 (organ confined) and pT3 (locally advanced) disease (P ¼ 0.0018). We also determined the levels of circulating NAALADL2 RNA found in the peripheral blood and found a significant increase in patients with biopsy confirmed prostate cancer compared with those with a raised PSA but negative biopsy who were assumed to be largely benign (Figure 1g ). NAALADL2 overexpression predicts poor survival As NAALADL2 was particularly highly expressed in locally advanced disease compared with organ-confined disease, we investigated whether NAALADL2 expression correlated with biochemical recurrence. Using the Cambridge TMA, it was found that 38/104 patients had biochemical recurrence but despite showing a trend that higher expression leads to poorer prognosis, it was not statistically significant, probably because of the small cohort size (P ¼ 0.56, Supplementary Figure S2A ). Using the 
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Karolinska TMA that had a larger cohort and longer follow-up leading to greater number of recurrence events (101/252), we demonstrated that increased NAALADL2 expression was able to predict for recurrence (P ¼ 0.0021, Figure 2a and Table 2 ). Using this data, Kaplan-Meier curves were generated showing that low NAALADL2 expression, that is, an immunoreactivity product (IRP) of o3 79.9% of patients had no relapse at 5 years ( Figure 2b ). 18 , we examined the ability of NAALADL2 to predict poor survival in low-risk patients (all primary T2 tumours with a low Gleason (5-6)) and showed that patients with high NAALADL2 expression had a significantly lower 5-year survival (93% (low expression) versus 45% (high expression); P ¼ 0.015) (Figure 2c ).
NAALADL2 is localized to the basal cell surface and promotes cell adhesion, migration and invasion The localization of NAALADL2 to the basal cell surface was in marked contrast to the apical membrane localization of PSMA/ NAALAD1 (Figure 3a) . Using confocal microscopy of the LNCaP The IRP index was categorized into three groups (0-3, 3-5 and 45) with the lowest category used as reference group and time-to-event analysis used as the outcome to generate Kaplan-Meier curves. (c) NAALADL2 expression was also examined in a previously published data set in low-risk patients (all primary T2 tumours with a low Gleason (5-6)) 18 and Kaplan-Meier curves generated using Galaxy. Overexpression of NAALADL2 in colon tumours was confirmed using a small commercial TMA. A cutoff of greater than or equal to weak staining was used to calculate sensitivity, specificity, PPV and NPV. P-values were calculated using a two-tailed t-test. n ¼ the number of cores examined. (c) NAALADL2 expression in prostate tissue was also ascertained by IHC using a TMA made in Cambridge. Sensitivity, specificity, PPV and NPV were calculated using a greater than or equal to moderate cutoff. P-values were calculated using a two-tailed t-test. n ¼ the number of distinct regions examined. (d) Results were confirmed using an independent TMA from the Karolinska Institute. IRP represents IRP. n ¼ the number of patients. P-values were calculated using a two-tailed t-test. (e) Data from the Cambridge TMA was stratified by Gleason grade (G3-G5). n ¼ the number of distinct regions examined. P-values were calculated using a Kruskal-Wallis test. (f ) Data from the Cambridge TMA was also stratified by pathological stage pT2 (organ confined), pT3 (localized spread to seminal vesicles), pT4 (spread to adjacent organs, for example, bladder and more distant metastases). N and P-values were calculated as for Gleason grade. (g) Whole blood was collected from patients using the PAXgene system to allow the isolation of circulating RNA that was analysed by qPCR for circulating NAALADL2 RNA. P-values were calculated using a two-tailed t-test.
prostate cancer cell line stably overexpressing NAALADL2, we were able to show that NAALADL2 is localized to the plasma membrane ( Figure 3b , upper panel), and in particular to the leading edge of cellular extensions ( Figure 3b , lower panel). The sub-cellular location of NAALADL2 expression led us to hypothesize that NAALADL2 overexpression may encourage cancer progression by promoting the interaction and movement of tumour cells through the extracellular matrix surrounding tumourigenic prostate glands.
To investigate this hypothesis, two cell lines were generated based upon the endogenous expression of NAALADL2; in LNCaP cells, in which NAALADL2 expression is low, NAALADL2 was stably overexpressed (LNCaP-NAALADL2 or LNCaP-empty vector (EV)), and in LNCaP-BIC cells, in which NAALADL2 expression is high, NAALADL2 was stably knocked down (LNCaP-BIC-siNAALADL2 or LNCaP-BIC-non-targeting (NT) small interfering RNA (siRNA)). Changes in expression were confirmed by western blotting, quantitative PCR (qPCR) and IHC (Supplementary Figure S1) .
As NAALADL2 was expressed on the basal cell surface, we investigated if overexpressing or knocking down NAALADL2 expression would alter binding to extracellular matrix proteins using a cell adhesion assay. When NAALADL2 was overexpressed, cells showed significantly increased adhesion to collagen and fibrinogen but not fibronectin or laminin ( Figure 3c , upper panel). When NAALADL2 expression was reduced, cells adhered less well to fibronectin and fibrinogen, although only fibronectin was statistically significant (P ¼ 0.017) ( Figure 3c , lower panel). Overexpression of NAALADL2 significantly enhanced cell migration and invasion in LNCaP stable cell lines (Figures 3d and e respectively), whereas knocking down NAALADL2 expression resulted in a significant decrease.
The effect of NAALADL2 in transforming cells using a soft agar colony-forming assay was also investigated. LNCaP-NAALADL2 cells formed significantly more colonies, whereas NAAL-BIC-siNAALADL2 cells had a significant reduction in colony-forming ability (Figure 3f ), suggesting that NAALADL2 may confer some transforming ability.
NAALADL2 is co-expressed with androgen-regulated genes To establish the role of NAALADL2 in prostate cells, the RNA from LNCaP stable cell lines were analysed using expression arrays (Figures 4a and b) . The LNCaP-NAALADL2-overexpressing cells showed gene enrichment ligands, kinases and transcription factors (Table 3 ). Pathway analysis showed that the overexpression of NAALADL2 led to alterations in pathways including epithelialto-mesenchyme transition, cell adhesion, cytoskeletal remodelling, immune response and apoptosis ( Figure 4b , Table 4 ). Data from the LNCaP-siNAALALD2 and LNCaP-NAALAADL2 stable cells was analysed to identify reciprocally differentially regulated genes (which went up in the overexpressing cell lines and down in the knockdown cells or vice versa). In total, nine genes were found to be reciprocally regulated with seven genes that overexpressed when NAALADL2 was overexpressed, and two genes showed reduced expression when NAALADL2 was overexpressed (Figures 4a and c and Table 5 ). The majority of these genes expressed proteins that were secreted or localized to the membrane ( Figure 4d ). Of these nine co-expressed genes, the expression of 7/9 could be validated by qPCR (Figure 4e ). Of these, AGR2 and Spondin 2 are known as prostate cancer biomarkers. [19] [20] [21] [22] [23] Using IHC on human prostate tissue, we were able to show that AGR2 and NAALADL2 were overexpressed in the same tumour cells (Figure 5a ).
Of the reciprocally identified genes identified all those confirmed by qPCR have been shown to be androgen regulated (Table 5) . Androgen regulation of the co-expressed genes was confirmed by treating LNCaP cells with the synthetic dihydrotestosterone, R1881, and performing qPCR after 6, 18, 24 and 28 h (Figure 5b and Supplementary Figure S3A ). We demonstrated strong upregulation of AGR2 in response to androgen, whereas weaker responses were seen for SPON2 and HSPA5. HRPDL, MMP7, HN1 and XAGE1B showed downregulation in response to androgen treatment. These data were supported by previously published data from our group (Supplementary Figure S3B) . 24 NAALADL2 showed no evidence of androgen regulation. The NAALADL2-co-expressed gene, HN1, has The ability of the LNCaP stable cell lines to form colonies in soft agar was assayed using the CytoSelect 96-well soft agar colony formation cell transformation Assay was inoculated with 1250 cells and grown for 7 days. Agar was melted and CyQuant GR-stained cells were measured using a 480/520-nm filter. For all assays, P-values were calculated using a two-tailed t-test between control and knockdown or overexpression cell lines. been shown to regulate androgen receptor (AR) and activation of the MAPK pathway. 25 Previously, HNRPL has been shown to be upregulated in castrate-resistant prostate cancer shown to activate the epidermal growth factor receptor. 26 Using a MAPK protein array, we looked for changes in members of the MAPK pathway ( Figure 5c ). This identified an upregulation of Ser 133 phospho-CREB, a protein known to be involved in cancer cell proliferation, survival and migration, in NAALADL2 overexpressing cells, and the 
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DISCUSSION
The NAALADase protein family are therapeutically interesting due to their ability to act as matrix metalloproteases and alter the tumour microenvironment. 1 This is exemplified by PSMA/ NAALAD1, a prostate cancer biomarker currently under investigation as a drug target and imaging tool. 5, [28] [29] [30] We identified NAALADL2 as being overexpressed in a number of tissues similar to PSMA/NAALAD1; however, unlike PSMA/ NAALAD1, we also saw expression in colon tumours as well as prostate adenocarcinoma (Table 1 and Figure 1) . 31 The diagnostic ability of NAALADL2 to distinguish between tumour and benign cells was confirmed in both colon and prostate cancers (Figures 1b-d) . In prostate cancer, an increase in expression of NAALADL2 correlated with increased Gleason grade and pathological stage (Figures 1e and f) . In particular, there was a significant difference between organ-confined pT2 prostate cancer and pT3 tumours that had invaded local structures such as the seminal vesicles. This suggests that NAALADL2 might promote more aggressive disease in which tumour cells are more likely to metastasize (P ¼ 0.018, Figure 1f) .
Although clinical markers such as Gleason grade and stage have been shown to have prognostic ability, very few molecular markers are used for prognosis in clinical practice. Serum PSA at diagnosis can be used as a prognostic indicator but PSA IHC is not prognostic. 32 Using an independent TMA, NAALADL2 IHC was shown to be prognostic for recurrence even after correction for clinical variables ( Figure 2 and Table 2 ). Although there was an overlap in the confidence intervals, the HRs were significantly different (P ¼ 0.036), indicating that more sensitive tests, such as circulating RNA (Figure 1g) , might improve the specificity of NAALADL2 to enable it to be used in clinical practice.
Unlike the apical location of PSMA/NAALAD1 (Figure 3a) , NAALADL2 was consistently localized to the basal membrane of cells in contact with the extracellular matrix. To study the function of NAALADL2 in prostate cancer cell lines were made stably overexpressing or knocking down NAALADL2 (Supplementary Figure S1) . Owing to the low expression of NAALADL2 in LNCaP cells, this cell line was used for the overexpression, and the higher expressing LNCaP-BIC cell line was used for the knockdown cells (Supplementary Figure S1A) . Although reciprocal changes in cell adhesion were not always seen, cells with increased NAALADL2 expression tended to exhibit increased adhesion, whereas those with reduced NAALADL2 showed reduced adhesion to extracellular matrix proteins (Figure 3c ). Cells expressing higher levels of NAALADL2 also showed increased invasion and migration, with reciprocal changes in the knockdown cell line (Figures 3d and e) . Similar changes were also seen in colonyforming ability, with overexpressing cells more able to have anchorage-independent growth (Figure 3f ). Taken together, these results suggest that increases in NAALADL2 expression in tumour cells could promote an interaction with the extracellular matrix surrounding the tumour glands and provides a potential mechanism for cells to escape the prostatic capsule and metastasize. [33] [34] [35] This would be consistent with an increased recurrence following radical prostatectomy that would have required cells to have breached the surgical margins ( Figure 2b and Table 2) .
To elucidate cellular function of NAALADL2 in tumours, expression arrays were performed on LNCaP-overexpressing stable cell lines (LNCaP-NAALADL2), showing changes to epithelial-to-mesenchyme transition and cell adhesion pathways (Table 4) . Using the LNCaP knockdown and overexpression stable cell lines (LNCaP-BIC-siNAALADL2 and LNCaP-NAALADL2), genes that showed reciprocal changes in expression in the knockdown and overexpression cell lines were identified ( Figure 4) . These genes included a number of androgen-regulated genes and known cancer biomarkers including AGR2 that is known to promote proliferation and metastases in a number of cancers, including prostate, where blood and urine tests have been developed for its diagnostic and prognostic use (Figure 5b) . [19] [20] [21] 36, 37 We were able to show that tumour cells overexpressing AGR2 also showed raised levels of NAALADL2, confirming its role as a diagnostic biomarker (Figure 5a ). SPON2 has recently been published as a specific marker of prostate cancer that has previously been shown to have diagnostic utility in other cancer types, and is also known to promote cell migration and invasion. 22, 38 Another highly co-expressed gene was the mitochondrial peptidase MIPEP that has been shown to cleave Notch and promote cell migration and motility. 39 Also co-expressed with NAALADL2 was HN1, a known AR regulator that regulates ubiquitination of the AR while also activating the MAP kinase pathway, a proposed mechanism of progression to castrate-resistant prostate cancer. 25, 40, 41 We established that raised NAALADL2 expression increased the amount of the CREB-activating phosphorylation at Ser 133 , previously shown to increase cell proliferation, migration and invasion 27 ( Figure 5c ). In combination, these NAALADL2-co-regulated genes, and their impact on master regulators of prostate gene expression such as the AR and CREB, help to establish a pro-migratory, pro-metastatic tumour microenvironment when NAALADL2 expression is increased.
MATERIALS AND METHODS
TMA and patient cohorts
Cambridge TMA: Prostate tissue from radical prostatectomies performed at Addenbrookes Hospital, Cambridge, UK between 2001 and 2005 were used to make TMAs using duplicate 0.6 mm cores taken from paraffinembedded tissue and a Beecher Manual TMA Arrayer as previously described. 42 Pathological stage and Gleason grade was confirmed by a specialist uro-pathologist (AYW).
Cambridge mini-TMA: Prostate tissue collected as above was used to make a test array containing 16 Â 6 mm cores including benign and tumour.
Karolinska TMA: Prostate tissue from radical prostatectomies performed at Karolinska Hospital, Stockholm, Sweden between 1998 and 2002 was used to make TMAs using 31 mm cores taken from paraffin-embedded tissue and a Beecher Manual Arrayer. In total, tumour tissue from 257 different patients was used to generate the TMA. Malignant tissue was identified and obtained from at least one and up to three different tumour foci from each patient. Pathological stage and Gleason grade was confirmed by a specialist uro-pathologist (LE) before scoring any IHC staining. Median follow-up was 61 months and based upon prostate cancer-related deaths.
A multi-tumour/normal TMA (Stretton Scientific, Stretton, UK) containing two tumour and one normal core from prostate, oesophagus, liver, thyroid, 
Only differentially expressed genes with a P-value of o1 Â 10 À 3 were used in the analysis. Actual is the number of network objects in the data set for the given protein class. Expected ¼ the mean value for hypergeometric distribution. The ratio is (actual/expected). The z-score is ((actualexpected)/sqrt(variance)). Table 6 . (c) Following analysis to identify reciprocally expressed genes seven genes were found that were both upregulated in the LNCaP-NAALADL2 cell line (OvExp_UP) and downregulated in the LNCaP-BIC-siNAALADL2 cell line (KD_DN; left diagram). Two genes were found that were downregulated in the LNCaP-NAALADL2 cell line (OvExp_DN) and upregulated in the LNCaP-BIC-siNAALADL2 cell line (KD_UP; right diagram). (d) The majority of reciprocally regulated genes were membranous or secreted (black) with the remainder nuclear (grey) or mitochondrial (white). (e) Co-expressed genes were confirmed by qPCR using SDH1 as a housekeeping gene. All results are shown relative to the EV or NT controls. Black bars represent the LNCaP-NAALADL2 cell line, whereas grey bars represent the LNCaP-BIC-siNAALADL2 cell line.
tongue, soft tissue lymphoma, breast, colon, stomach, tongue, skin, lung, kidney, ovary, uterus, testes, pancreas and thymus was used to investigate NAALADL2 specificity. Colon, pancreas and breast TMAs (Stretton Scientific) were used for validation. The breast TMA was composed of two tissue cores from 30 cases of invasive ductal carcinoma (total 60 cores). The pancreas TMA included two tissue cores from 30 cases of pancreatic adenocarcinoma, as well as eight non-neoplastic cores (total 68 cores). The colon TMA comprised 2 spots each of 45 tissue cores and 8 non-neoplastic cores (total 98 cores).
Immunohistochemistry
All IHC was performed using a Leica Bondmax Autostainer (Milton Keynes, UK). NAALADL2 was stained using 1.5 M Tris EDTA, pH 8.0, for antigen recovery and rabbit anti-NAALADL2 antibody (1:25, Atlas Antibodies, Stockholm, Sweden) diluted in a buffer containing 300 mM Tris-buffered saline, 1% donkey serum (Sigma-Aldrich, St Louis, MO, USA) and 0.05% Tween. AGR2 was stained using rabbit anti-AGR2 antibody (1:100; Atlas Antibodies) and 20 min antigen retrieval in citrate buffer. Nuclei were counterstained with haematoxylin and slides were coverslipped using DPX. Dual staining of NAALADL2 and AGR2 was completed on sequential mini-TMA sections using the polymer refine Kit for AGR2 and the Leica FDABehx protocol with 20 min antigen retrieval in citrate buffer and rabbit anti-AGR2 diluted (1:50) in bond diluent. This was immediately followed by the Leica JJM protocol using a polymer refine red detection for NAALADL2 with a 10-min pre-treatment with 1.5 M Tris EDTA, pH 8.0 and rabbit ant-NAALADL2 (1:100) diluted in Bond diluent. Abbreviations: Pathway analysis was performed using GeneGo Metacore on expression array data from LNCaP cells stably transfected with either empty vector or an NAALADL2 overexpression construct. Only differentially expressed genes with a p-value of o1 Â 10 À 3 were used in the analysis Only statistically significant result are show grouped into functional categories EMT, epithelial-to-mesenchyme transition; NAALADL2, N-acetyl-L-aspartyl-L-glutamate peptidase-like 2. Only differentially expressed genes with a P-value of o1 Â 10 À 3 were used in the analysis. Only statistically significant results are shown grouped into functional categories.
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IHC scoring and data analysis
Cambridge TMA: All regions of each core were scored giving rise to multiple scores for adjacent regions in a core (scoring performed by HCW and AYW). The TMA was scored as none (no staining), weak (staining was inconsistent and/or weak), moderate (appreciable staining) or strong (very intense staining). Karolinska TMA: Each core scored (by LE and AS) by intensity and proportion of cancer cells stained on the scale 0-3. Average values of the three intensity and proportion scorings were calculated to give average intensity and proportion values. These values were then multiplied to give the IRP.
Sensitivity, specificity, positive predictive values (PPVs) and negative predictive values (NPVs) were calculated where possible. All grouped P-values (n ¼ X3) were calculated using a Kruskal-Wallis test. All pairwise comparisons were completed using a Mann-Whitney test.
Thirty-eight patients in the Cambridge TMA had biochemical recurrences and median follow-up was 86 months (range 0-145 months), hence Kaplan-Meier curves could be created for prognostic information. The Karolinska TMA had a median follow-up of 61 months (range 1-144 months). For Kaplan-Meier curves for the Karolinska TMA time-toevent analysis was generated using biochemical recurrence as outcome. Association between IRP index and biochemical recurrence was assessed using Cox regression analysis to estimate HRs with corresponding 95% confidence intervals as measure for association. The IRP index was categorized into three groups (0-3, 3-5 and 45) with the lowest category used as reference group. Both crude analysis and analysis adjusted for age, Gleason score, extraprostatic extension, positive surgical margin, vesicle invasion, clinical stage and preoperative PSA were carried out.
Extraction of circulating RNA from whole blood Blood (2.5 ml) was collected in a PAXgene tube from patients enrolled in the ProMPT trial (National Institute of Health and Research ID 5837) and stored according to the manufacturer's instructions. Samples were collected from patients with various grades of prostate cancer (Gleason 3 þ 3, 3 þ 4, 4 þ 3 and 4 þ 4/5). RNA was extracted using the PAXgene RNA Blood kit (Qiagen, Limburg, The Netherlands). The benign men all had raised PSA but negative biopsy, indicating that a proportion (B30%) will have undetected cancers. cDNA production and qPCR RNA was reverse transcribed using High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Paisley, UK). Primer sequences are given in Table 6 . Reverse transcription-PCR were performed in triplicate in 10 ml reactions containing 5 ml of SYBR Green PCR Master Mix (Applied Biosystems), 2 pmol of primers and 10 ng of cDNA template. Ct values were calculated for all conditions and the expression of target genes was normalized against the expression of SDH1 or UBC housekeeping genes using the ddCt method.
Cell lines
LNCaP cells, LNCaP-BIC (LNCaP cells that were continuously passaged in media supplemented with 1 mM bicalutamide) and PC3 cells were grown in RPMI (Invitrogen, Paisley, UK) supplemented with 10% foetal bovine serum. For the androgen timecourse, cells were incubated for 48 h in phenol redfree RPMI supplemented with charcoal-stripped foetal bovine serum (Hyclone, Waltham, MA, USA). Cells were incubated with 1 nM R1881 (Sigma) for 0, 6, 18, 24 and 48 h before harvesting. Data is presented as a timecourse or box and whisker plot of all time points with the median value indicated. Androgen-regulated gene expression was confirmed using the GSE18684 data set available through GEO. 24 These data were generated by expression profiling of LNCaP cells grown in the presence or absence of androgens (1 nM R1881), with 36 samples taken over a 24-h period. Data were normalized and plotted using the R statistical software, with values centred on the triplicate time-zero data points.
Stable cell lines with overexpressed and knockdown NAALADL2
For the NAALADL2 overexpressing cell line, NAALADL2 was cloned from LNCaP cDNA using XbaI and HpaI restriction sites into the pCSC lentiviral vector using the primers shown in Table 6 . As a control, empty pCSC vector was used. For the NAALADL2 knockdown cells, short hairpin RNA (shRNA) sequences were created by annealing two oligonucleotides (Table 6 ) and cloned into the pSICOR lentiviral vector using HpaI and XhoI restriction sites. 43 NT shRNA were used as a control. HEK293T cells were transfected with pCSC -NAALADL2 (or empty pCSC) and pSICOR-shNAALADL2 (or NT vector) using calcium phosphate, alongside envelope and third-generation
Empty Vector
Non-targeting siRNA siNAALADL2 NAALADL2 overexpression 
RNA expression array
Gene expression analysis was carried out on Illumina Human HT12 version 4 arrays (San Diego, CA, USA) using six biological replicates from each cell line (LNCaP-EV, LNCaP-NAALADL2 overexpressing, LNCaP-BIC-NT siRNA, LNCaP-BIC-siNAALADL2, PC3-NAALADL2 overexpressing and PC3-EV). All analyses were carried out on R using Bioconductor packages. 44 Raw intensity data was processed using the BASH and HULK algorithms as implemented in the beadarray package. 45, 46 Log2 transformation and quantile normalization of the data was performed across all sample groups. Differential expression analysis was carried out using the limma package. 47 Differentially expressed genes were selected using a P-value cutoff o0.05 after application of false discovery rate (FDR) correction for multiple testing applied globally to correct for multiple contrasts. For pathway analysis, Metacore (Thomson Reuters, New York City, NY, USA) was used by utilizing data from the LNCaP-EV versus LNCaP-NAALADL2 overexpression and PC3-EV versus PC3-NAALADL2 overexpression arrays. Gene enrichment by function and pathway analysis was completed on both data sets.
Western blot analysis
Cell lysates were made and western blots were run as described previously 48 , and probed using the following antibodies: anti-NAALADL2 antibody (1:100, Atlas Antibodies); anti-tubulin (1:10 000) and anti-actin 
Confocal microscopy
The samples were prepared as described previously 49 and stained with anti-NAALADL2 antibody (1:200, Atlas Antibodies) and actin (1:500, Abcam). To visualize, cells were incubated with 488-or 405-conjugated Alexafluor secondary antibodies (1:10 000, Molecular Probes, Paisley, UK), washed and mounted with Vectorshield containing 4 0 ,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories Inc., Peterborough, UK). Images were taken using a Nikon eclipse 90i confocal microscope (Nikon, Surrey, UK) with Â 60 objective.
Cell adhesion assay
Cell adhesion was measured with CytoSelect 48-well cell fluorometric extracellular matrix adhesion assay (Cell Biolabs, San Diego, CA, USA) by seeding 1.5 Â 10 5 cells in serum-free media and incubating at 37 1C for 90 min. After washing, bound cells were lysed with 1 Â lysis buffer/ CyQuant GR dye solution and measured using a 480/520-nm filter. All P-values are calculated using a two-tailed t-test with Po0.05 being classed as significant.
Cell migration and invasion assay
Cell migration was assayed with CytoSelect 96-well cell migration fluorometric assay (Cell Biolabs). Each well contained a Boyden chamber with a 8-mm pore polycarbonate membrane and media containing 10% Table 6 . Primer sequences used for cloning NAALADL2 into pCSC lentiviral vector for stable cell line production and for qPCR validation of CGCTCTAGAACCATGGGAGAGAATGAAGCAAGTT  TCAATTCTTCCCATCCAAGA  shRNA NAALADL2  GAAGCAAGTTTACCTAACATTCAAGAGATGTTAGGT  AAA-CTTGCTTCTTTTTTC   TCGAGAAAAAAGAAGCAAGTTTACCTAACA  TCTCTTGAATGTTAGGTAAACTTGCTTCA  shRNA control  TGTTCTCCGAACGTGTCACGTTCAAGAGA  CGTGACACGTTCGGAGAACTTTTTTC   TCGAGAAAAAAGTTCTCCGAACGTGTCACGTCT  CTTGAACGTGACACGTTCGGAGAACA  NAALADL2  CACCAAAGAGCAATCGCTGCAACT  TGAAGATGGAGCATCTGAAGGGCA  PSA  GCCTTCCCTGTACACCAAG  AGTCTTGGCCTGGTCATTTC  HSPA5  TAGCGTATGGTGCTGCTGTC  TTTGTCAGGGGTCTTTCACC  ARG2  AGCACTAGTGGGTGGGATTG  GCAAGAATGCTGACACTGGA  MMP7  GAGTGCCAGATGTTGCAGAA  AAATGCAGGGGGATCTCTTT  HN1  CCTTCTTGGTGTTGCCCTAA  ATCAGCCAGCCAGTCTTGTT  XAGE1B  TCTGCAAGAGCTGCATCAGT  TTGCGTTGTTTCAGCTTGTC  S1PR3  GCTTCAGGAAATGGAAGCTG  TCAGGATGCTGTGAAACTGC  MIPEP  AAGGGACTGCTCTGGTGCTA  GGCACTCAGCTCAGGAACTC  SPON2  GGCCAAATACAGCATCACCT  CCTCGATCTCCTTCATCAGC  HNRPDL  TGAAGGGGGAGTGAGAATTG  CCCCTCCCCAATAAACTTGT  SDH1  TGGGAACAAGAGGGCATCTG were confirmed by western blotting using anti-Ser 133 -CREB (1:1000) and total CREB (1:1000). Tubulin (1:10 000) was used a loading control.
foetal bovine serum as a chemoattractant. Chambers were loaded with 1.5 Â 10 5 cells in serum-free media and incubated at 37 1C for 24 h. Cells within wells were washed away and migratory cells were collected using the cell detachment solution. Cells were stained with CyQuant GR dye and measured as before. Invasion was assayed with CytoSelect 96-well cell invasion fluorometric assay (Cell Biolabs). Each well contained an 8-mm pore Boyden chamber overlayed with extracellular matrix and media containing 10% foetal bovine serum. Chambers were loaded with 1.5 Â 10 5 cells in serum-free media and incubated as before. Cells that passed through the membrane were stained with CyQuant GR dye and measured as before. All P-values are calculated using a two-tailed t-test with Po0.05 being classed as significant.
Colony formation assay
The ability of cells to form colonies in soft agar was assayed using the CytoSelect 96-well soft agar colony formation cell transformation assay (Cell Biolabs). Each well was inoculated with 1250 cells and incubated for 7 days at 37 1C. Each assay was set up with four biological replicates. Anchorage-independent growth was quantified by melting the agar and staining cells with CyQuant GR dye before being measured as before.
